Historical Valuation
Icecure Medical Ltd (ICCM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.00 is considered Undervalued compared with the five-year average of -5.42. The fair price of Icecure Medical Ltd (ICCM) is between 1.14 to 2.51 according to relative valuation methord. Compared to the current price of 0.70 USD , Icecure Medical Ltd is Undervalued By 38.51%.
Relative Value
Fair Zone
1.14-2.51
Current Price：0.70
38.51%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Icecure Medical Ltd (ICCM) has a current Price-to-Book (P/B) ratio of 4.67. Compared to its 3-year average P/B ratio of 5.87 , the current P/B ratio is approximately -20.46% higher. Relative to its 5-year average P/B ratio of 5.76, the current P/B ratio is about -18.93% higher. Icecure Medical Ltd (ICCM) has a Forward Free Cash Flow (FCF) yield of approximately -31.73%. Compared to its 3-year average FCF yield of -26.96%, the current FCF yield is approximately 17.68% lower. Relative to its 5-year average FCF yield of -24.98% , the current FCF yield is about 27.04% lower.
P/B
Median3y
5.87
Median5y
5.76
FCF Yield
Median3y
-26.96
Median5y
-24.98
Competitors Valuation Multiple
AI Analysis for ICCM
The average P/S ratio for ICCM competitors is 3.79, providing a benchmark for relative valuation. Icecure Medical Ltd Corp (ICCM.O) exhibits a P/S ratio of 4.00, which is 5.38% above the industry average. Given its robust revenue growth of 28.40%, this premium appears sustainable.
Performance Decomposition
AI Analysis for ICCM
1Y
3Y
5Y
Market capitalization of ICCM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ICCM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ICCM currently overvalued or undervalued?
Icecure Medical Ltd (ICCM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.00 is considered Undervalued compared with the five-year average of -5.42. The fair price of Icecure Medical Ltd (ICCM) is between 1.14 to 2.51 according to relative valuation methord. Compared to the current price of 0.70 USD , Icecure Medical Ltd is Undervalued By 38.51% .
What is Icecure Medical Ltd (ICCM) fair value?
ICCM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Icecure Medical Ltd (ICCM) is between 1.14 to 2.51 according to relative valuation methord.
How does ICCM's valuation metrics compare to the industry average?
The average P/S ratio for ICCM's competitors is 3.79, providing a benchmark for relative valuation. Icecure Medical Ltd Corp (ICCM) exhibits a P/S ratio of 4.00, which is 5.38% above the industry average. Given its robust revenue growth of 28.40%, this premium appears sustainable.
What is the current P/B ratio for Icecure Medical Ltd (ICCM) as of Jan 09 2026?
As of Jan 09 2026, Icecure Medical Ltd (ICCM) has a P/B ratio of 4.67. This indicates that the market values ICCM at 4.67 times its book value.
What is the current FCF Yield for Icecure Medical Ltd (ICCM) as of Jan 09 2026?
As of Jan 09 2026, Icecure Medical Ltd (ICCM) has a FCF Yield of -31.73%. This means that for every dollar of Icecure Medical Ltd’s market capitalization, the company generates -31.73 cents in free cash flow.
What is the current Forward P/E ratio for Icecure Medical Ltd (ICCM) as of Jan 09 2026?
As of Jan 09 2026, Icecure Medical Ltd (ICCM) has a Forward P/E ratio of -5.73. This means the market is willing to pay $-5.73 for every dollar of Icecure Medical Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Icecure Medical Ltd (ICCM) as of Jan 09 2026?
As of Jan 09 2026, Icecure Medical Ltd (ICCM) has a Forward P/S ratio of 4.00. This means the market is valuing ICCM at $4.00 for every dollar of expected revenue over the next 12 months.